Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3

Issei Kawashima; Yuri Kawashima; Yasuo Matsuoka; Kiyotaka Fujise; Hideki Sakai; Mari Takahashi; Toshiaki Yoshikawa; Tetsuya Nakatsura; Takeshi Ishihara; Tadao Ohno

doi:10.1002/ccr3.279

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3

Clin Case Rep. 2015 Jun;3(6):444-7. doi: 10.1002/ccr3.279. Epub 2015 Apr 17.

Authors

Affiliations

¹ Hikarigaoka Clinic Green-town Hikarigaoka 4-10-10, Kashiwa, Chiba, 277-0062, Japan.
² Hikarigaoka Clinic Green-town Hikarigaoka 4-10-10, Kashiwa, Chiba, 277-0062, Japan ; National Cheng Kung University 1 University Road, Tainan 701, Taiwan.
³ Fujise Internal Medicine Clinic Minamikashiwachuo 1-6, Kashiwa, Chiba, 277-0075, Japan.
⁴ Kashiwa Municipal Hospital Fuse1-3, Kashiwa, Chiba, 277-0825, Japan.
⁵ Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Kashiwa, Chiba, 277-8577, Japan.
⁶ Cell-Medicine, Inc. Sengen 2-1-6, Tsukuba Science City, Ibaraki, 305-0047, Japan.

Abstract

Autologous formalin-fixed tumor vaccine (AFTV) suppressed re-recurrence for more than 32 months of multiple-recurrent hepatocellular carcinoma based on hepatitis C virus-induced liver cirrhosis in a case with previous recurrence interval, 51-, 28-, 12-, and 4-months. We detected glypican-3-specific cytotoxic T lymphocytes in the peripheral blood at 12 months after AFTV.

Keywords: Cytotoxic T lymphocyte; glypican-3; hepatocellular carcinoma; tumor vaccine.

Publication types

Case Reports